Category Archives: Analysis

Timber Pharma: Calling All Shareholders, Vote Now Or Lose Your Money

B 14/11/2023 Comments Off

Summary Timber Pharmaceuticals is the subject of a merger offer by Danish LEO Pharma. In two previous shareholder meetings, not enough shareholders voted to approve the offer. If the merger with LEO Pharma is not… Read more

Realm Therapeutics: A Cash Grab In Progress

B 03/06/2019 No Comments

Summary

Realm Therapeutics has, pending shareholder approval, agreed to be acquired by ESSA Pharma. ESSA’s unattractive bid is in illiquid stock and strongly undervalues Realm’s cash position. Realm’s board and large shareholders clearly have a… Read more

DARA Biosciences: An Attractive Short Term Merger Play

B 30/11/2015 Comments Off

Summary

DARA is planning to be acquired by UK-listed Midatech Pharma. Midatech’s offer to DARA shareholders consists of ADRs as well as a CVR based on certain milestones. After the deal is completed Midatech’s ADRs… Read more

KaloBios: Martin Shkreli Vs. The Rest Of The World

B 23/11/2015 Comments Off

Summary

The share price of troubled bio-tech KBIO exploded last week after Martin Shkreli bought a majority stake. Shkreli was appointed CEO and secured 13 million dollar in financing. Shkreli bought KBIO because of a… Read more